Cumulative Irritation Assessment of Topical Formulations in Healthy Volunteers: A Patch Test Study

The primary objective of the "Jim Beam Cumulative Irritation Patch Test" is not explicitly stated. The study involves **healthy volunteers** and aims to evaluate the potential for cumulative irritation caused by a specific product or substance. Understanding the irritation potential is clinically relevant as it helps in assessing the safety profile of the product, ensuring it does not cause adverse skin reactions over repeated exposure. No secondary objectives are provided in the available data.

The clinical trial involves **healthy volunteers** as the study population, encompassing both male and female participants. The age range of the participants is categorized under code "3," which typically includes adults. The trial does not focus on a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria and lifestyle considerations such as diet, physical activity, or habits have not been specified. The trial population was selected to include a general representation of healthy individuals without specific inclusion or exclusion criteria being highlighted.

The clinical trial is designed as a **Phase 1** study involving **healthy volunteers**. The trial is expected to commence on July 22, 2025, and conclude by August 20, 2025. The study employs a randomized, double-blind, controlled methodology to ensure the reliability and validity of the results. Participants will be involved in the trial for a duration that aligns with the overall trial timeline, with specific involvement periods determined by the study protocol.

The sequence of study visits begins with an inclusion visit, also known as the screening visit, where potential participants are assessed for eligibility based on predefined criteria. This visit is crucial for ensuring that only suitable candidates are enrolled in the trial. Following successful inclusion, participants will attend a series of follow-up visits. These visits are scheduled at regular intervals to monitor the participants' health status and any potential reactions to the interventions being tested. The end-of-study visit marks the conclusion of the participant's involvement, where final assessments are conducted to gather comprehensive data on the study's outcomes.

Participants are expected to adhere to the study schedule and protocol throughout their involvement. However, certain conditions may necessitate early termination from the study. These conditions include, but are not limited to, adverse reactions, non-compliance with study procedures, or withdrawal of consent by the participant. The trial's design and procedures are structured to prioritize participant safety while achieving the study's scientific objectives.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the provided data, further details about the **experimental medication** and any **non-experimental treatments** used in the study are not available. The trial documentation does not include information about the **product role**, **product authorization status**, or the **origin of the active substances** involved in the trial.

The clinical trial is designed to assess the efficacy of the investigational product. The trial is categorized as a Phase 1 study, which typically focuses on evaluating the safety, tolerability, and pharmacokinetics of the product in a small group of participants. Although specific efficacy endpoints are not detailed, Phase 1 trials often include preliminary assessments of efficacy to inform future studies. The trial is scheduled to commence recruitment on July 22, 2025, with an estimated completion date of August 20, 2025. The efficacy assessments will be conducted in accordance with the trial protocol, utilizing appropriate methodologies and tools to ensure accurate and reliable data collection and analysis. The results from this trial will contribute to the understanding of the investigational product's potential therapeutic benefits and inform subsequent phases of clinical research.